FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2105404902> ?p ?o ?g. }

• W2105404902 endingPage "344" @default.
• W2105404902 startingPage "335" @default.
• W2105404902 abstract "The efficacy, safety and tolerability of linezolid was compared with teicoplanin in a randomized, controlled, open-label, multicentre study of 430 patients with suspected or proven Gram-positive infection. Patients received intravenous (iv) +/- oral linezolid 600 mg every 12 h (n = 215) or iv or intramuscular teicoplanin (n = 215) for up to 28 days. Clinical outcomes in the intent-to-treat (ITT) and clinically-evaluable populations and microbiological success rates in microbiologically evaluable patients were assessed at follow-up (test of cure). Investigator assessed clinical cure rates at end of treatment (EOT) in ITT patients treated with linezolid (95.5%) were superior to those of teicoplanin (87.6%) for all infections combined, indicating a 7.9% statistically significant treatment advantage for linezolid (P = 0.005, 95% CI: 2.5, 13.2). Clinical cure rates by baseline diagnosis were consistently higher at EOT for the linezolid versus teicoplanin groups with skin and soft tissue infection (96.6% versus 92.8%), pneumonia (96.2% versus 92.9%) and bacteraemia (88.5% versus 56.7%). The 31.8% treatment advantage in bacteraemic patients (but not for those seen in the other infection categories) for linezolid-treated patients was statistically significant (P = 0.009, 95% CI: 10.2, 53.4). Bacterial eradication rates for linezolid exceeded those of teicoplanin for all infection sites combined but this did not reach statistical significance (81.9% versus 69.8%, respectively; P = 0.056). Adverse event rates were similar between the treatment groups, were mild to moderate in severity, and resolved quickly following treatment. The linezolid group experienced a higher incidence of drug related adverse events (30% versus 17%; P = 0.002), and notably of gastrointestinal effects (13.0% versus 1.9%, P = 0.001). However, antibiotic discontinuation rates as a result of drug related adverse events were similar (4.7% in the linezolid group versus 3.7%). Linezolid was clinically superior to teicoplanin in the treatment of Gram-positive infections." @default.
• W2105404902 created "2016-06-24" @default.
• W2105404902 creator A5027928189 @default.
• W2105404902 date "2004-01-16" @default.
• W2105404902 modified "2023-10-14" @default.
• W2105404902 title "Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections" @default.
• W2105404902 cites W10985232 @default.
• W2105404902 cites W128488591 @default.
• W2105404902 cites W1826993504 @default.
• W2105404902 cites W1968518177 @default.
• W2105404902 cites W1971172216 @default.
• W2105404902 cites W1975150477 @default.
• W2105404902 cites W1975850307 @default.
• W2105404902 cites W1985261796 @default.
• W2105404902 cites W1985648453 @default.
• W2105404902 cites W1992486144 @default.
• W2105404902 cites W1996164000 @default.
• W2105404902 cites W2001028523 @default.
• W2105404902 cites W2012030567 @default.
• W2105404902 cites W2020727483 @default.
• W2105404902 cites W2028378915 @default.
• W2105404902 cites W2045752721 @default.
• W2105404902 cites W2079824217 @default.
• W2105404902 cites W2098093207 @default.
• W2105404902 cites W2108051304 @default.
• W2105404902 cites W2109093571 @default.
• W2105404902 cites W2115089466 @default.
• W2105404902 cites W2116816874 @default.
• W2105404902 cites W2128076923 @default.
• W2105404902 cites W2138752606 @default.
• W2105404902 cites W2143949361 @default.
• W2105404902 cites W2149375508 @default.
• W2105404902 cites W2157572113 @default.
• W2105404902 cites W2160104373 @default.
• W2105404902 cites W2165301082 @default.
• W2105404902 cites W2167299810 @default.
• W2105404902 cites W2276443311 @default.
• W2105404902 cites W2329427515 @default.
• W2105404902 cites W2768146862 @default.
• W2105404902 cites W2733797709 @default.
• W2105404902 doi "https://doi.org/10.1093/jac/dkh088" @default.
• W2105404902 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14729745" @default.
• W2105404902 hasPublicationYear "2004" @default.
• W2105404902 type Work @default.
• W2105404902 sameAs 2105404902 @default.
• W2105404902 citedByCount "104" @default.
• W2105404902 countsByYear W21054049022012 @default.
• W2105404902 countsByYear W21054049022013 @default.
• W2105404902 countsByYear W21054049022014 @default.
• W2105404902 countsByYear W21054049022015 @default.
• W2105404902 countsByYear W21054049022016 @default.
• W2105404902 countsByYear W21054049022017 @default.
• W2105404902 countsByYear W21054049022018 @default.
• W2105404902 countsByYear W21054049022020 @default.
• W2105404902 countsByYear W21054049022021 @default.
• W2105404902 countsByYear W21054049022022 @default.
• W2105404902 countsByYear W21054049022023 @default.
• W2105404902 crossrefType "journal-article" @default.
• W2105404902 hasAuthorship W2105404902A5027928189 @default.
• W2105404902 hasBestOaLocation W21054049021 @default.
• W2105404902 hasConcept C126322002 @default.
• W2105404902 hasConcept C141071460 @default.
• W2105404902 hasConcept C168563851 @default.
• W2105404902 hasConcept C197934379 @default.
• W2105404902 hasConcept C2776703206 @default.
• W2105404902 hasConcept C2777914695 @default.
• W2105404902 hasConcept C2778375690 @default.
• W2105404902 hasConcept C2778980435 @default.
• W2105404902 hasConcept C2779489039 @default.
• W2105404902 hasConcept C2781414143 @default.
• W2105404902 hasConcept C3019249092 @default.
• W2105404902 hasConcept C501593827 @default.
• W2105404902 hasConcept C523546767 @default.
• W2105404902 hasConcept C54355233 @default.
• W2105404902 hasConcept C71924100 @default.
• W2105404902 hasConcept C86803240 @default.
• W2105404902 hasConcept C89423630 @default.
• W2105404902 hasConcept C90924648 @default.
• W2105404902 hasConceptScore W2105404902C126322002 @default.
• W2105404902 hasConceptScore W2105404902C141071460 @default.
• W2105404902 hasConceptScore W2105404902C168563851 @default.
• W2105404902 hasConceptScore W2105404902C197934379 @default.
• W2105404902 hasConceptScore W2105404902C2776703206 @default.
• W2105404902 hasConceptScore W2105404902C2777914695 @default.
• W2105404902 hasConceptScore W2105404902C2778375690 @default.
• W2105404902 hasConceptScore W2105404902C2778980435 @default.
• W2105404902 hasConceptScore W2105404902C2779489039 @default.
• W2105404902 hasConceptScore W2105404902C2781414143 @default.
• W2105404902 hasConceptScore W2105404902C3019249092 @default.
• W2105404902 hasConceptScore W2105404902C501593827 @default.
• W2105404902 hasConceptScore W2105404902C523546767 @default.
• W2105404902 hasConceptScore W2105404902C54355233 @default.
• W2105404902 hasConceptScore W2105404902C71924100 @default.
• W2105404902 hasConceptScore W2105404902C86803240 @default.
• W2105404902 hasConceptScore W2105404902C89423630 @default.
• W2105404902 hasConceptScore W2105404902C90924648 @default.
• W2105404902 hasIssue "2" @default.
• W2105404902 hasLocation W21054049021 @default.

• next